Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915225 | 0.79 | GPR84 (0.40) | GPR84NPC1RAB9AXDHLMNA | |
| SCHEMBL10514376 | 0.78 | KDM4E (0.50) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL4197676 | 0.77 | RAB9A (0.49) | NPC1RAB9AXDHSMN1; SMN2KDM4E | |
| SCHEMBL4192105 | 0.76 | CYP1A2 (0.41) | GPR84NPC1RAB9AXDHMAPT | |
| SCHEMBL5915139 | 0.75 | GPR84 (0.39) | GPR84NPC1RAB9AXDHLMNA | |
| SCHEMBL5915134 | 0.75 | GPR84 (0.41) | GPR84LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL26113985 | 0.74 | SMN1; SMN2 (0.47) | GPR84XDHLMNAMAPTSMN1; SMN2 | |
| SCHEMBL5915172 | 0.73 | ALDH1A1 (0.38) | GPR84LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5915150 | 0.73 | NPC1 (0.48) | NPC1RAB9ALMNASMN1; SMN2HPGD | |
| SCHEMBL5915136 | 0.73 | CYP1A2 (0.51) | GPR84NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247280-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | claimed |
| US-20060247280-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247280-A1 | Compounds and methods | METAP2, DNPEP, METAP1 | GPR84 1358/4885NPC1 3549/4885RAB9A 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.